4.7 Article

Pharmacogenomics in clinical trials: an overview

期刊

FRONTIERS IN PHARMACOLOGY
卷 14, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2023.1247088

关键词

pharmacogenomics; pharmacogenetics; clinical trials; personalised medicine; clinical pharmacology; clinical research

向作者/读者索取更多资源

With the trend towards promoting personalised medicine, the application of pharmacogenetics and pharmacogenomics is becoming increasingly important. Clinical trials that include pharmacogenetic and pharmacogenomic information can improve knowledge about the effectiveness and safety of new drugs, with a focus on areas such as oncology and mental health. Training in pharmacogenetics and pharmacogenomics is necessary for researchers and clinicians to properly interpret the data and contribute to better prescribing decisions and patient care, ultimately leading to the implementation of personalised medicine.
With the trend towards promoting personalised medicine (PM), the application of pharmacogenetics and pharmacogenomics (PGx) is of growing importance. For the purposes of clinical trials, the inclusion of PGx is an additional tool that should be considered for improving our knowledge about the effectiveness and safety of new drugs. A search of available clinical trials containing pharmacogenetic and PGx information was conducted on ClinicalTrials.gov. The results show there has been an increase in the number of trials containing PGx information since the 2000 s, with particular relevance in the areas of Oncology (28.43%) and Mental Health (10.66%). Most of the clinical trials focus on treatment as their primary purpose. In those clinical trials entries where the specific genes considered for study are detailed, the most frequently explored genes are CYP2D6 (especially in Mental Health and Pain), CYP2C9 (in Hematology), CYP2C19 (in Cardiology and Mental Health) and ABCB1 and CYP3A5 (particularly prominent in Transplantation and Cardiology), among others. Researchers and clinicans should be trained in pharmacogenetics and PGx in order to be able to make a proper interpretation of this data, contributing to better prescribing decisions and an improvement in patients' care, which would lead to the performance of PM.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据